Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-111 in acute sudden sensorineural hearing loss
NCT02809118Phase 3Terminated
- Sponsor
- Altamira Therapeutics
- Start
- Jun 2016
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 3
01
Overview
A Phase 3 trial of brimapitide in idiopathic sudden sensorineural hearing loss (ISSNHL), sponsored by Altamira Therapeutics. Started Jun 2016; status: terminated.
02
Drugs
brimapitide
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NCT02809118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02809118.